Optimer Initiates Phase 3b Clinical Trial of DIFICID® for the Prevention of Clostridium difficile-Associated Diarrhea …
JERSEY CITY, N.J., Nov. 1, 2012 /PRNewswire/ — Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the first patient has been dosed in its DEFLECT-1, Phase 3b clinical trial of DIFICID® …
